Valensa Joins Algae Biomass Organization to Drive Innovation In Microalgae Nutraceuticals

5585952d-1835-4493-a102-50053a308b41articleimage.jpg

15 Jun 2017 --- Valensa International has joined the Algae Biomass Organization (ABO), a major trade association for the algae industry, thereby joining the growing ranks of companies and organizations that are becoming part of the ABO to create awareness about microalgae as a sustainable source of human nutrition, animal feed, water treatment services, chemicals, fuels and countless other products. 

“The ABO’s mission is to ‘promote the development of viable commercial markets’ for products derived from Algae. Valensa is a ‘disruptive innovator’ in microalgae-based nutraceuticals, creating safe, sustainable indication-specific solutions for enhanced health. The power of algae-based nutraceuticals is just emerging on the world scene, and the ABO is getting the word out,” C.P. Umasudhan, CEO at Valensa International, tells NutritionInsight.

“We are excited to have industry leader Valensa join the Algae Biomass Organization’s efforts to expand the availability of algae-based products in dozens of markets,” says Matt Carr, executive director of the ABO. “Valensa’s experience commercializing advanced technologies in human health and nutrition are among the most important for an industry that is just beginning show its potential to provide new products, improve global sustainability, and trigger new economic growth.”

Click to EnlargeHeadquartered in Eustis, Florida, Valensa International is a leading designer of science-based, naturally-sourced proprietary blends of ingredients for nutritional supplements and functional foods. Valensa International holds more than 60 US and International Patents for Formulations and Manufacturing (Deep Extract Supercritical CO2 and O2B Peroxidation Blocker stabilization.) 

“Valensa and affiliate Parry Nutraceuticals have been diligently working on expanding the scope of microalgae production technology including controlled race-way cultures, hybrid closed systems and fermentation technology needed to create safe, efficacious, microalgae-based nutraceuticals,” Umasudhan says. 

Valensa’s scientific team specializes in developing clinical research and intellectual property to introduce unique condition-specific formulations. 

“While applications for microalgae are unlimited, Valensa is producing condition specific algae-based products for eye, cardio and joint health. Valensa’s science team is also working on products that will revolutionize the Immune Health category in both nutraceuticals and functional foods. Retailers and consumers are demanding the next generation in immunity care and the future is promising,” Umasudhan tells NutritionInsight.

Additionally, Valensa has completed clinical work, and continues clinical research, to improve the standard of care in the Immune Health category. Several microalgae approaches have already shown great promise, according to Uma. Valensa is currently in the process of defining microalgae strains and commercialization technology to manufacture algae-derived omega 3 fatty acids (EPA, DHA).

“Exclusive algae-based formulations will become the next generation of nutraceuticals to accommodate growing consumer demand for safe, healthy, sustainable-sourced and all-natural products,” says Umasudhan. “We look forward to building the future of sustainable algae with the support of the ABO.”

“The ABO was created with the overwhelming belief that our future needs lie in the development of microalgae. Some microalgae, like Spirulina, were developed to provide high-quality nutrition to the world. Hybrid open and closed water systems in rural areas, with sustainable production, are set to compete with, or surpass, land or ocean based farming in the near future,” Umasudhan says. 

“The application of spirulina, chlorella and haematococcus pluvialis derived astaxanthin have not yet even scratched the surface of their potential for nutraceutical, functional foods, natural colorant and pharmaceuticals. Valensa, and affiliate Parry Nutraceuticals, are also looking to bring the next generation of plant-based, clean, sustainable omega 3’s to the market. Valensa’s core strategy is to conduct clinical trials and license  intellectual property to enable their customers to sell products that are efficacious and differentiated,” Umasudhan concludes.

Related Articles

Business News

Natural ingredients key for Evonik's growth strategy

23 Aug 2017 --- With an expanding portfolio that includes omega 3 fatty acids and anthocyanin-rich extracts, global specialty chemicals company Evonik Industries is boldly expanding its presence in the Advanced Food Ingredients market. NutritionInsight spoke with Dr. Ludger Eilers, Director of Evonik Health Care’s Food Ingredient Segment, about this move as well as the company’s latest R&D projects and ingredients.

Nutrition & Health News

Plant-based diets associated with lower levels of plasma lipids by meta-analysis

23 Aug 2017 --- Consumption of vegetarian diets, particularly vegan diets, is associated with lower levels of plasma lipids, which could offer individuals and healthcare professionals an effective option for reducing the risk of heart disease or other chronic conditions. This is the finding of a review and meta-analysis by Dr. Yoko Yokoyama, Ms. Susan Levin and Dr. Neil Barnard.

Nutrition & Health News

"Silent" food product reformulation key to helping consumers buy fewer calories

23 Aug 2017 --- Without notifying consumers explicitly, supermarkets could help their customers consume fewer calories by making small changes to the recipes of own-brand food products to reduce the calories contained in the product. This is according to researchers at the University of Copenhagen, who say that so-called “silent” product reformulation may be a promising strategy to allow food retailers to contribute to lower calorie intake in the population.

Food Ingredients News

Nexira Fibregum receives FODMAP friendly certification

23 Aug 2017 --- Natural and organic ingredients company Nexira has announced that its Fibregum product has been certified FODMAP friendly in Australia. The company describes Fibregum as an “all-natural range, with a guaranteed minimum content of 90 percent dietary fibers.” Nexira notes that the FODMAP Friendly program is the only registered certification trademark in the world, making Fibregum’s certification big news for the company. The program’s laboratory tests the FODMAP levels in food and gives the certification to the ones low in FODMAP.

Nutrition & Health News

Adding oats to gluten-free diet is safe for celiac sufferers, study review suggests

23 Aug 2017 --- No evidence has been found by researchers that addition of oats to a gluten-free diet affects symptoms, histology, immunity or serologic features of patients with celiac disease. This is according to a systemic review and meta-analysis of clinical and observational studies.

More Articles
URL : http://www.nutritioninsight.com:80/news/valensa-joins-algae-biomass-organization-to-drive-innovation-in-microalgae-nutraceuticals.html